Research programme: influenza monoclonal antibody therapeutics - ContraFect/Trellis

Drug Profile

Research programme: influenza monoclonal antibody therapeutics - ContraFect/Trellis

Alternative Names: Anti-H1 mAb - ContraFect; Anti-H3 mAb - ContraFect; Anti-Influenza mAb combination - ContraFect; CF 401; CF 402; CF 403; CF 404

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trellis Bioscience
  • Developer ContraFect; Trellis Bioscience
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza A virus infections; Influenza B virus infections

Most Recent Events

  • 03 Aug 2017 ContraFect Corporation has patent protection for intranasal delivery of CF 404 for the treatment of Influenza in USA
  • 03 Aug 2017 Updated pharmacodynamics data from a preclinical trial in Influenza released by ContraFect Corporation
  • 10 May 2016 ContraFect announces intention to submit IND in second mid of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top